Jun 28, 2025, 15:41

DoD FY25 Prostate Cancer Research Program Clinical Consortium Award

Supports the development and maintenance of a multi-institutional consortium—comprising one Coordinating Center and multiple Clinical Research Sites—to rapidly execute phase 2 and phase 1/2 prostate cancer clinical trials that address high-impact therapeutic interventions and quality-of-life challenges in Service Members, Veterans, and the broader patient population.

Eligibility Criteria:

Applicant Organizations: Extramural and intramural entities (academic institutions, biotech companies, foundations, DOD laboratories, etc.), U.S. or foreign, for-profit or non-profit.
Principal Investigator: Independent investigator with a faculty-level appointment (or equivalent) by award activation; no citizenship restrictions.
Mechanism Options:
- Coordinating Center: Must demonstrate capacity to administer consortium infrastructure, coordinate clinical trials (phase 2/1 & 2), manage data, ensure FDA/IRB compliance, and support ≥2 affiliate sites.
- Clinical Research Site: Must provide patient accrual (≥25 patients/year with ≥5% from high-risk or military populations), trial proposals (≥2/year), and adherence to consortium procedures.
Research Scope: Phase 2 or phase 1/2 trials only; clinical protocol development is not supported. Observational clinical research permitted; interventional trials beyond phase 2 excluded.

Funding Details:

Coordinating Center:
- Total Cost Cap: 10.5 USD million over up to 4 years
- Use of Funds: Consortium administration, trial coordination, data management, affiliate site support ($500K/year per site), meetings, infrastructure, personnel, travel, and sustainability planning.
Clinical Research Sites:
- Total Cost Cap: 2.0 USD million over up to 4 years
- Use of Funds: Patient accrual operations, trial introduction, data collection, personnel, meetings, and travel to scientific/technical conferences.
Payment Schedule: Quarterly in U.S. currency to the host institution; no indirect-cost restrictions beyond negotiated rates.

Deadlines:

Letter of Intent (pre-application): August 8, 2025 by 5:00 p.m. ET
Full Application: August 29, 2025 by 11:59 p.m. ET
Application Verification Ends: September 3, 2025 by 5:00 p.m. ET
Peer Review: October 2025
Programmatic Review: February 2026

Where to Go for Further Information & Application:

eBRAP (intramural DOD): (select FOA HT942525PCRPCCA)
Program Guidelines & General Instructions.

cancer CDMRP clinical research clinical-consortium consortium-grant data management DoD-funding eBRAP Grants.gov military health OncoDaily Oncology phase-2-trials prostate cancer translational research

King Albert II’s Brave Battle: A Decade of Fighting Skin Cancer

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification